Asfotase Alfa
Brand name: Strensiq
Rank #143 of 500 drugs by total cost
$113.8M
Total Cost
1,142
Total Claims
$113.8M
Total Cost
48
Prescribers
$100K
Cost per Claim
0
Beneficiaries
1,147
30-Day Fills
$2.4M
Avg Cost/Provider
24
Avg Claims/Provider
About Asfotase Alfa
Asfotase Alfa (sold as Strensiq) was prescribed 1,142 times by 48 Medicare Part D providers in 2023, costing the program $113.8M. At $100K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 140 | Memantine Hcl (Memantine Hcl) | $117.5M | 2,268,098 |
| 141 | Estradiol (Estradiol) | $115.7M | 1,412,386 |
| 142 | Vortioxetine Hydrobromide (Trintellix) | $113.9M | 197,873 |
| 143 | Asfotase Alfa (Strensiq) | $113.8M | 1,142 |
| 144 | Erenumab-Aooe (Aimovig Autoinjector) | $111.9M | 118,455 |
| 145 | Corticotropin (Acthar) | $111.6M | 1,633 |
| 146 | Bupropion Hcl (Bupropion Hcl Sr) | $110.0M | 3,323,724 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology